Featured publications

Persistence of antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre

Barilaro, G; Coloma-Bazan, E; Chacur, A; Della Rocca, C; Perez-Isidro, A;

(...)

Penella, DT; Reverter, JC; Andujar, AM; Cervera, R; Espinosa, G.

Reference:
Autoimmunity Reviews 2022.
Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre

Araujo, O; Hernandez-Rodriguez, J; Pelegrin, L; Feliu, M; Boland, M;

Hernandez-Negrin, H; Adan, A; Espinosa, G; Cervera, R.

Reference:
Lupus 2022.
Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry

Hunt, AR; Nguyen, V; Creuzot-Garcher, CP; Alforja, S; Gabrielle, PH;

(...)

McAllister, IL; O'Toole, L; Gillies, MC; Barthelmes, D; Mehta, H.

Reference:
British Journal Of Ophthalmology 2022.
Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection

Espinosa, G; Zamora-Martinez, C; Perez-Isidro, A; Neto, D; Bravo-Gallego, LY;

Prieto-Gonzalez, S; Vinas, O; Moreno-Castano, AB; Ruiz-Ortiz, E; Cervera, R.

Reference:
Frontiers In Immunology 2022.
Creation of a Neovascular Age-related Macular Degeneration National Database using a web-based platform: Fight Retinal Blindness SPAIN

Zarranz-Ventura, J; Parrado-Carrillo, A; Nguyen, V; Sararols, L; Garay-Aramburu, G;

Puzo, M; Arruabarrena, C; Figueras-Roca, M; Gillies, MC; Casaroli-Marano, RP.

Reference:
Clinical And Experimental Ophthalmology 2022.
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

Almeida-Brasil, CC; Hanly, JG; Urowitz, M; Clarke, AE; Ruiz-Irastorza, G;

(...)

Khamashta, MA; Bruce, IN; Inanc, M; Abrahamowicz, M; Bernatsky, S.

Reference:
Annals Of The Rheumatic Diseases 2022.
Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry

Gabrielle, PH; Nguyen, V; Creuzot-Garcher, C; Miguel, L; Alforja, S;

(...)

Casaroli-Marano, RP; Zarranz-Ventura, J; Gillies, M; Arnold, J; Barthelmes, D.

Reference:
Acta Ophthalmologica 2022.
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome

Drosos GC; Vedder D; Houben E; Boekel L; Atzeni F;

(...)

Voskuyl A; Macfarlane GJ; Ward MM; Nurmohamed MT; Tektonidou MG .

Reference:
Annals Of The Rheumatic Diseases 2022.
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

Alunno A; Najm A; Machado PM; Bertheussen H; Burmester GR;

(...)

Stamm TA; Tas SW; Terrier B; McGonagle DG; Mariette X.

Reference:
Annals Of The Rheumatic Diseases 2022.